Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinium Pharmaceuticals (ATNM)
NYSE MKT:ATNM
RESEARCH TOOLSreports
Actinium Pharmaceuticals (ATNM) Stock Price & Analysis
2,057 Followers
ATNM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $10.24
Previous Close$7.11
Volume19.65K
Average Volume (3M)252.88K
Market Cap
$215.04M
Enterprise Value$137.20M
Total Cash (Recent Filing)$84.06M
Total Debt (Recent Filing)$9.49M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 14, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding29,783,451
10 Day Avg. Volume202,975
30 Day Avg. Volume252,879
Standard Deviation0.23
R-Squared0.00073
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.96
Price to Sales (P/S)2687.86
Price to Cash Flow (P/CF)-7.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.69K
Enterprise Value/Gross Profit1.69K
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$29.40Price Target Upside307.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Actinium Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsActinium Pharmaceuticals presented positive data from the completed Phase 1b combination trial of Actimab-A and CLAG-M in patients with relapsed/refractory acute myeloid leukemia at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting.
Drug EfficacyThe combination of Actimab-A and CLAG-M produced high rates of response, measurable residual disease negativity, bone marrow transplant access, and improved survival outcomes in high-risk patients.
Preclinical DataNew preclinical data demonstrated that combining Actimab-A with a leading menin inhibitor significantly increased cell death and prolonged anti-tumor effects compared to single-agent therapy in xenograft leukemia models.
Bears Say
Adverse EventsMore than 10% of patients reported grade III/IV adverse events, including hematologic toxicities, infection, rash, and hypokalemia.
CommercializationLowering PT from $20 to $16 due to the delayed commercial launch of Iomab-B.
Financial ReportingDowngrading Shares to Hold due to Ongoing Financial Reporting Delays and Related Party Dispute Involving the CEO.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATNM FAQ
What was Actinium Pharmaceuticals’s price range in the past 12 months?
Actinium Pharmaceuticals lowest stock price was $4.00 and its highest was $10.24 in the past 12 months.
What is Actinium Pharmaceuticals’s market cap?
Currently, no data Available
When is Actinium Pharmaceuticals’s upcoming earnings report date?
Actinium Pharmaceuticals’s upcoming earnings report date is Mar 14, 2025 which is in 235 days.
How were Actinium Pharmaceuticals’s earnings last quarter?
Actinium Pharmaceuticals released its earnings results on Mar 15, 2024. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.57 by $0.23.
Is Actinium Pharmaceuticals overvalued?
According to Wall Street analysts Actinium Pharmaceuticals’s price is currently Undervalued.
Does Actinium Pharmaceuticals pay dividends?
Actinium Pharmaceuticals does not currently pay dividends.
What is Actinium Pharmaceuticals’s EPS estimate?
Actinium Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinium Pharmaceuticals have?
Actinium Pharmaceuticals has 29,783,451 shares outstanding.
What happened to Actinium Pharmaceuticals’s price movement after its last earnings report?
Actinium Pharmaceuticals reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.57. Following the earnings report the stock price went up 7.656%.
Which hedge fund is a major shareholder of Actinium Pharmaceuticals?
Among the largest hedge funds holding Actinium Pharmaceuticals’s share is Royce & Associates LLC. It holds Actinium Pharmaceuticals’s shares valued at 392K.
---
Actinium Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.40 (307.20% Upside)
$29.40 (307.20% Upside)
Blogger Sentiment
Bullish
ATNM Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Negative
Last 7 Days <0.1%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.79%
12-Months-Change
Fundamentals
Return on Equity
-91.92%
Trailing 12-Months
Asset Growth
-13.40%
Trailing 12-Months
Company Description
Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.
---
ATNM Stock 12 Month Forecast
Average Price Target
$29.40
▲(307.20% Upside)
Technical Analysis
Best Analysts Covering ATNM
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+7.94%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +7.94% per trade.
---